Company / Cash & Equivalents
Haemonetics Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$306.8M
FY2025
5-year range
$178.8M / $306.8M
FY2021-FY2025
Trend
+71.6%
vs FY2024
Sector context
#66 of 152
Health Care
What the data says
At $307M, Haemonetics's cash & equivalents ranks #66 of 152 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $115M in FY2016 to $307M in FY2025.
Based on SEC 10-K filings.
$307M in FY2025 with a 5-year CAGR of +17.4%.
Improved from $284M to $307M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +5.7%
- 5-Year CAGR
- +17.4%
- 10-Year CAGR
- -
Sector benchmark
#66 of 152 in Health CareTop 43% of 152This company $306.8M Sector average $1.2B
▼
-73.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 71.6% year-over-year.
- Ranks #66 out of 152 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $306.8M | +71.6% |
| FY2024 | $178.8M | -37.1% |
| FY2023 | $284.5M | +9.6% |
| FY2022 | $259.5M | +34.9% |
| FY2021 | $192.3M | +40.1% |
| FY2020 | $137.3M | -18.9% |
| FY2019 | $169.4M | -6.0% |
| FY2018 | $180.2M | +29.1% |
| FY2017 | $139.6M | +21.2% |
| FY2016 | $115.1M | -28.3% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026